Surf Dating Named The Official Dating App Partner of HYROX Americas
Surf was designed for users to spend less time on the app and more time on dates, offering users the opportunity to see all available singles in a grid-style view without endless swiping, and a filtering option to sort by fitness preferences and interests like pickleball, backpacking, and concerts not hidden behind a paywall. Now, as part of their partnership, when filtering on Surf you can select HYROX to see only other singles competing in or training for upcoming races.
HYROX offers the opportunity for participants to race as a single or as part of a doubles pair. At upcoming
"HYROX is tough, dating shouldn't be," says Surf CEO
As part of the partnership and Surf's commitment to spending more time developing in-person and authentic connections, they'll host pre-race shakeout runs, singles recovery events, and Station 9, the official after party and 9th station in HYROX's 8-station race.
You can visit Surf at select HYROX North American race locations in early 2026 including
Download Surf Dating and add the HYROX tag
Follow us on Instagram at Surf Dating and HYROX America.
Press Contact:
[email protected]
About Surf Dating
Founded in 2024, Surf Dating is a
About HYROX
HYROX is a global ecosystem of events, training, and coaching designed to inspire and impact 100 million lives. Built around a unique race format of 8 x 1 km runs and 8 workout stations, HYROX has established the gold standard in fitness racing and is driving toward Olympic recognition. By connecting the world's gym communities through the transformative power of training and competition, HYROX is the cultural heartbeat of fitness.
View original content to download multimedia:https://www.prnewswire.com/news-releases/surf-dating-named-the-official-dating-app-partner-of-hyrox-americas-302658591.html
SOURCE Surf Dating
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AI-empowered Pipeline-in-a-drug Option: Insilico Medicine Nominates ISM9077, Potential First-in-class Target Y Inhibitor, as Preclinical Candidate (PCC) for Ocular Diseases, Inflammatory Disorders and
- Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combination with Bevacizumab in Late-Line Advanced Colorectal
- EtherPR Enhances Crypto PR Distribution with Broader Blockchain Media Coverage
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share